Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
140 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Thalassemia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H1 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 6, 17 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively. Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders). - The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Thalassemia - Overview Thalassemia - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Thalassemia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Thalassemia - Companies Involved in Therapeutics Development Acceleron Pharma Inc Agios Pharmaceuticals Inc Alnylam Pharmaceuticals Inc bluebird bio Inc Calimmune Inc CRISPR Therapeutics Editas Medicine Inc Errant Gene Therapeutics LLC Gamida Cell Ltd Gilead Sciences Inc Incyte Corp Ionis Pharmaceuticals Inc IRBM Science Park SpA Johnson & Johnson Kiadis Pharma NV La Jolla Pharmaceutical Company Merck & Co Inc PharmaEssentia Corp Protagonist Therapeutics Inc Sangamo Therapeutics Inc Zydus Cadila Healthcare Ltd Thalassemia - Drug Profiles (decitabine + tetrahydrouridine) - Drug Profile Product Description Mechanism Of Action R&D Progress ACY-957 - Drug Profile Product Description Mechanism Of Action R&D Progress AG-348 - Drug Profile Product Description Mechanism Of Action R&D Progress ALN-TMP - Drug Profile Product Description Mechanism Of Action R&D Progress ambrisentan - Drug Profile Product Description Mechanism Of Action R&D Progress ATIR-201 - Drug Profile Product Description Mechanism Of Action R&D Progress BB-305 - Drug Profile Product Description Mechanism Of Action R&D Progress benserazide - Drug Profile Product Description Mechanism Of Action R&D Progress CAL-H - Drug Profile Product Description Mechanism Of Action R&D Progress CNTO-530 - Drug Profile Product Description Mechanism Of Action R&D Progress CordIn - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy for Sickle Cell Disease and Thalassemia - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate IGF2BP1 for Sickle Cell Disease and Thalassemia - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-2696277 - Drug Profile Product Description Mechanism Of Action R&D Progress IMR-687 - Drug Profile Product Description Mechanism Of Action R&D Progress IONISTMPRSS-6LRx - Drug Profile Product Description Mechanism Of Action R&D Progress LJPC-401 - Drug Profile Product Description Mechanism Of Action R&D Progress luspatercept - Drug Profile Product Description Mechanism Of Action R&D Progress M-009 - Drug Profile Product Description Mechanism Of Action R&D Progress M-012 - Drug Profile Product Description Mechanism Of Action R&D Progress NiCord - Drug Profile Product Description Mechanism Of Action R&D Progress PEG-EPO - Drug Profile Product Description Mechanism Of Action R&D Progress PHBB-101 - Drug Profile Product Description Mechanism Of Action R&D Progress PTG-300 - Drug Profile Product Description Mechanism Of Action R&D Progress RCY-1497 - Drug Profile Product Description Mechanism Of Action R&D Progress RNAi Gene Therapy for Sickle Cell Disease and Beta Thalassemia - Drug Profile Product Description Mechanism Of Action R&D Progress ruxolitinib phosphate - Drug Profile Product Description Mechanism Of Action R&D Progress SCD-101 - Drug Profile Product Description Mechanism Of Action R&D Progress sirolimus - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Beta Thalassemia and Sickle Cell Anemia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours - Drug Profile Product Description Mechanism Of Action R&D Progress sotatercept - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Beta Thalassemia - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Beta Thalassemia and Sickle Cell Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Beta Thalassemia and Sickle Cell Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Thalagen - Drug Profile Product Description Mechanism Of Action R&D Progress Thalassemia - Dormant Projects Thalassemia - Product Development Milestones Featured News & Press Releases Feb 06, 2017: Kiadis Pharma Provides Update on ATIR201 Dec 15, 2016: Kiadis Pharma announces initiation of Phase I/II clinical trial with ATIR201 for thalassemia Dec 14, 2016: bluebird bio Announces First Patient Treated with LentiGlobin Drug Product in Northstar-2 (HGB-207) Phase 3 Trial of Patients with Transfusion-Dependent �-Thalassemia Dec 06, 2016: bluebird bio Provides Updates on HSC Gene Therapy Programs Dec 05, 2016: Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology Dec 04, 2016: Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Gamma Globin (HBG) Protein Expression for the Treatment of Sickle Cell Disease and Beta-Thalassemia Dec 03, 2016: bluebird bio Presents New Data from HGB-205 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent �-Thalassemia and Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting Dec 02, 2016: Acetylon to present data on ACY-957 at the American Society of Hematology Annual Meeting Nov 21, 2016: CRISPR Therapeutics Announces Two Presentations Demonstrating the Potential for CRISPR Gene Editing To Treat Sickle Cell Disease and �-Thalassemia Nov 03, 2016: bluebird bio to Present New Data from Three LentiGlobin Clinical Studies at American Society of Hematology (ASH) Annual Meeting Oct 13, 2016: bluebird bio Provides Update on LentiGlobin Programs and Research and Development Strategy at Gene Therapy Day Sep 21, 2016: LentiGlobin Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency's PRIME Program Sep 08, 2016: bluebird bio Opens Phase 3 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia Sep 07, 2016: La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Thalassemia, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Thalassemia - Pipeline by Acceleron Pharma Inc, H1 2017 Thalassemia - Pipeline by Agios Pharmaceuticals Inc, H1 2017 Thalassemia - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017 Thalassemia - Pipeline by bluebird bio Inc, H1 2017 Thalassemia - Pipeline by Calimmune Inc, H1 2017 Thalassemia - Pipeline by CRISPR Therapeutics, H1 2017 Thalassemia - Pipeline by Editas Medicine Inc, H1 2017 Thalassemia - Pipeline by Errant Gene Therapeutics LLC, H1 2017 Thalassemia - Pipeline by Gamida Cell Ltd, H1 2017 Thalassemia - Pipeline by Gilead Sciences Inc, H1 2017 Thalassemia - Pipeline by Incyte Corp, H1 2017 Thalassemia - Pipeline by Ionis Pharmaceuticals Inc, H1 2017 Thalassemia - Pipeline by IRBM Science Park SpA, H1 2017 Thalassemia - Pipeline by Johnson & Johnson, H1 2017 Thalassemia - Pipeline by Kiadis Pharma NV, H1 2017 Thalassemia - Pipeline by La Jolla Pharmaceutical Company, H1 2017 Thalassemia - Pipeline by Merck & Co Inc, H1 2017 Thalassemia - Pipeline by PharmaEssentia Corp, H1 2017 Thalassemia - Pipeline by Protagonist Therapeutics Inc, H1 2017 Thalassemia - Pipeline by Sangamo Therapeutics Inc, H1 2017 Thalassemia - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017 Thalassemia - Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
